This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Staudt, A. Articles by Felix, S. B. Search for Related Content PubMed PubMed Citation Articles by Staudt, A. Articles by Felix, S. B. Related Collections Myocardial cardiomyopathy disease Other Treatment

(Circulation. 2001;103:2681.)
© 2001 American Heart Association, Inc.

Clinical Investigation and Reports

Immunohistological Changes in Dilated Cardiomyopathy Induced by Immunoadsorption Therapy and Subsequent Immunoglobulin Substitution

Alexander Staudt, MD; Frank Schäper, MD; Verena Stangl, MD; Andreas Plagemann, MD; Marco Böhm, MD; Kurt Merkel, MD; Gerd Wallukat, PhD; Klaus D. Wernecke, PhD; Karl Stangl, MD; Gert Baumann, MD; Stephan B. Felix, MD

From the Klinik für Innere Medizin B, Ernst-Moritz-Arndt-Universität, Greifswald (A.S., S.B.F.); the Institut für Pathologie (F.S.), Medizinische Klinik I (V.S., M.B., K.S., G.B.), Institut für Experimentelle Endokrinologie (A.P.), and Institut für Medizinische Biometrie (K.D.W.), Charité, Humboldt-Universität, Berlin; the Institut für Pathologie und Dermatohistologie, Diagnostisches Zentrum, Berlin (K.M.); and the Max Delbrück Zentrum für Molekulare Medizin, Berlin-Buch (G.W.), Germany.

Correspondence to Alexander Staudt, MD, Klinik für Innere Medizin B, Ernst-Moritz-Arndt-Universität, Loefflerstraße 23a, 17487 Greifswald, Germany. E-mail staudt{at}mail.uni-greifswald.de

	Abstract

Top Abstract Introduction Methods Results Discussion References

 
Background—Immunoadsorption (IA) and subsequent immunoglobulin (Ig) G substitution represent an additional therapeutic approach in dilated cardiomyopathy (DCM). It remains to be elucidated whether this treatment modulates myocardial inflammation, which is possibly a causal factor of ventricular dysfunction.

Methods and Results—From 25 DCM patients (EF <30%), 12 patients were randomized for IA therapy and subsequent IgG substitution at 1-month intervals until month 3. Before (<7 days) and after IA therapy, right ventricular biopsies were obtained from all patients. Biopsies were also obtained at intervals of 3 months from 13 patients without IA/IgG treatment (controls). IA/IgG treatment induced improvement in left ventricular ejection fraction from 21.3±1.7% (±SEM) to 27.0±1.3% (P<0.01 versus baseline/controls) and reduction of the ß-receptor autoantibody serum levels (P<0.01 versus baseline/controls). The number of CD3 cells decreased from 5.7±0.8 to 2.9±0.5 cells/mm² (P<0.01 versus baseline/controls). This decline was paralleled by a decrease in CD4 (P<0.01 versus baseline/controls) and CD8 (P<0.05 versus baseline/controls) lymphocytes. The number of leukocyte common antigen–positive cells (leukocytes) was reduced from 20.0±3.2 to 9.9±2.8 cells/mm² (P<0.01 versus baseline/P<0.05 versus controls). HLA class II expression decreased from 2.1±0.7% to 1.1±0.4% (P<0.05 versus controls/baseline). The number of immunopositive cells and the expression of HLA class II in controls remained stable. In both groups, the degree of fibrosis remained unchanged.

Conclusions—IA and subsequent IgG substitution mitigate myocardial inflammation in DCM.

Key Words: cardiomyopathy • immunology

	Introduction

Top Abstract Introduction Methods Results Discussion References

 
Dilated cardiomyopathy (DCM) is a myocardial disease characterized by progressive depression of myocardial contractile function and by ventricular dilatation.¹

Experimental and clinical data suggest a causal relationship between myocarditis and DCM. Inflammatory processes may be involved in the pathogenesis of DCM and may represent one important factor causing progression of ventricular dysfunction. Immunohistological methods have been successfully introduced for diagnosis of myocardial inflammation, allowing identification and quantification of inflammatory cells.^{2 3} Infiltration with lymphocytes and mononuclear cells, as well as increased HLA-antigen expression, are frequent phenomena in DCM. These findings support the hypothesis that the immune process is still active.

Disturbances in both humoral and cellular immunity have been described in myocarditis and DCM patients.^{4 5} Subsequent myocyte necrosis induced by these immune reactions can result in fibrosis as a common phenomenon in DCM. The relative contributions of cellular and humoral immune disturbances to the pathogenesis and progression of DCM have not been determined. According to an experimental model of myocarditis induced by myosin, myocardial damage is mediated by T lymphocytes.⁶ The role of T lymphocytes in DCM is still unclear. Indices of T-cell activation have been described in a substantial proportion of DCM.^{4 7}

A number of antibodies against cardiac cell proteins have been identified in DCM, eg, antibodies against mitochondrial proteins, contractile proteins, cardiac ß₁-receptors, and muscarinergic receptors.^{8 9 10 11 12} The functional role of cardiac autoantibodies is still unclear. They may reflect an inflammatory response to myocyte necrosis, thereby representing an epiphenomenon. Cardiac autoantibodies may also play an active role in the pathogenesis of DCM, however, by initiating the disease process or contributing to the progression of myocardial contractile malfunction. If cardiac autoantibodies contribute to cardiac malfunction in DCM, their removal would be expected to improve myocardial function. Cardiac antibodies are extractable by immunoadsorption (IA).^{13 14 15} Intravenous administration of immunoglobulin (Ig) also influences the cellular and humoral immune system by different mechanisms.¹⁶

An initial uncontrolled pilot study and a randomized study were performed to ascertain the short-term and prolonged hemodynamic effects of IA and subsequent IgG substitution in DCM patients.^{13 14} The cardiac index rose immediately, and systemic vascular resistance simultaneously fell. IA and IgG substitution were repeated at monthly intervals until month 3. Acute hemodynamic improvement persisted over this period.¹⁴ In contrast, the hemodynamic situation did not improve among control patients. It remains to be elucidated whether IA and subsequent IgG substitution not only improve hemodynamics but also modulate myocardial inflammation in DCM. The present study accordingly investigated immunohistological changes induced by IA therapy and subsequent IgG substitution in patients with DCM compared with controls without immunomodulatory therapy.

	Methods

Top Abstract Introduction Methods Results Discussion References

 
Study Protocol
Twenty-five DCM patients were admitted. Patients with positive evidence of the ß₁-receptor autoantibody, with borderline as well as apparent signs of myocardial inflammation (lymphocytes >2.4 cells/mm²), were included. This limit was chosen because, in patients without inflammatory heart disease (coronary heart disease, valvular heart disease, and hypertrophic cardiomyopathy), the number of CD3-positive cells was <2.4 lymphocytes/mm².² Twelve patients were randomized (closed-label) for treatment with IA and subsequent IgG substitution (IA/IgG group) at monthly intervals until month 3. In 13 patients (controls), conventional therapy was continued without IA/IgG treatment. Biopsies (n=5 to 8) were obtained from all patients from the interventricular septum of the right ventricle at baseline, before the study began (<7 days), and after 3 months. Right ventricular biopsies from the septum interventriculare were used instead of left ventricular biopsies to avoid risk of cerebral embolization. All patients demonstrated left ventricular dysfunction (left ventricular ejection fraction, LVEF, <30%, as assessed by 2D echocardiography), as well as symptoms of severe chronic heart failure (NYHA functional class III to IV). Coronary heart disease was excluded by angiography. Patients were excluded if they had suffered from active infectious diseases, cancer, chronic alcoholism, or heart failure of known origin (eg, primary valvular disease). All patients were treated with ACE inhibitors, digitalis, and diuretics. Twelve patients received nitrates (IA/IgG group, n=7; controls, n=5). Sixteen patients were treated with a ß-blocker (IA/IgG group, n=8; controls, n=8). In these cases, doses of ß-blockers had been stable for 6 months before the present study. All patients had received stable oral medication for >3 months before the study. Medication and dosage for the treatment group did not differ significantly from those for controls.

Written consent was obtained from each patient, and the protocol was approved by the Charité Hospital Ethics Committee.

Immunoadsorption
Ig extraction from the plasma took place with Ig-Therasorb (Baxter), an immunoadsorber for Ig as described recently.¹⁴ In the IA/IgG group, IA was performed in 4 courses at 1-month intervals until month 3. After every final IA session, the patients received 0.5 g/kg polyclonal IgG (Venimmun-N) to restore IgG plasma levels.

Clinical Findings
Echocardiographic parameters were determined in both groups by 2D echocardiography performed at baseline and after 3 months. The readings were recorded, and a reader blinded to the treatment group performed offline assessment of LVEF and left ventricular internal diameter in systole (LVIDs) and in diastole (LVIDd). LVEF was measured according to the Simpson rule.

Determination of ß₁-receptor autoantibodies took place as described elsewhere.^{15 17 18}

Histological Examination
Biopsies were fixed in 5% formaldehyde and embedded in paraffin. Slices 2 µm thick were cut and investigated by light microscopy in series of 8 to 10 pieces after staining with hematoxylin-eosin and for connective tissue (elastica–van Gieson). This procedure was intended to exclude myocarditis according to the Dallas criteria and to determine the degree of fibrosis, the latter by means of computer-assisted image analysis. Immunohistological stainings were done by the labeled streptavidin-biotin method. Primary antibodies were anti-CD3, -CD4, -CD8, –leukocyte common antigen (LCA), and HLA class II antigens (DP, DQ, DR). Manufacturers were Dako and Novacastra. Antibodies against LCA labeled all leukocytes, and antibodies against CD3, CD8, and CD4 labeled T lymphocytes. Immunopositive cells were counted under high-power magnification (x400) by 2 independent observers in blinded mode. The density of HLA class II antigen expression and the degree of fibrosis were ascertained by computer-assisted image analysis (Contron). For this purpose, the microscopic image was depicted on a 17-in screen, stored in a frame grabber, and analyzed pixel by pixel. Every pixel with color values within previously defined ranges was set as "1," and every other pixel was "0." The total number of "1" pixels provided exact measurement of the immunopositive/elastica–van Gieson–positive area. This area was calculated as percentage area of the biopsy plane. Each biopsy was investigated stepwise, with 10 steps per biopsy.

Statistics
Results are expressed as mean±SEM. We applied the paired Wilcoxon test to detect changes within treatment groups. Differences between the 2 treatments were investigated by the Mann-Whitney U test. For study of the lymphocytes CD3, CD4, and CD8 versus treatment groups, we performed a 2-factor ANOVA, followed by Bonferroni-Holm–adjusted post hoc analyses. Changes in NYHA classification after treatment were analyzed by singly ordered 2x4 contingency tables using the exact Kruskal-Wallis test of identically distributed rows (for treatments). Significance was assessed at the P<0.05 level.

	Results

Top Abstract Introduction Methods Results Discussion References

 
Characteristics of Patients at Baseline
The Table lists clinical characteristics, echocardiographic parameters, immunohistological findings, and ß-receptor autoantibody levels at baseline. In the control group and IA/IgG group, the following data were comparable: age, sex, disease duration, NYHA classification, ß-receptor autoantibody level, and immunohistochemical findings. LVEF, LVIDs, and LVIDd were also similar in both groups.

View this table: [in this window] [in a new window]   Table 1. Characteristics of Patients at Baseline

Clinical Findings
All patients tolerated IA and subsequent IgG substitution well. No major complications such as infection, major bleeding, or worsening of renal function occurred.

After 3 months’ evaluation of echocardiographic parameters, ß-receptor autoantibody levels of the control group were comparable to those at baseline when the study began (Figure 1).

View larger version (9K): [in this window] [in a new window]   Figure 1. Changes in LVEF as assessed by echocardiography in IA/IgG group (solid bars; n=12) and in control group (open bars; n=13). *P<0.05, **P<0.01 significantly different from baseline; +P<0.05, ++P<0.01 significantly different from controls

In the IA/IgG group, the ß-receptor autoantibody level decreased from 4.3±0.3 to 1.1±0.4 relative units (P<0.01 versus baseline/controls). Simultaneously, LVEF increased significantly in the IA/IgG group, from 21.3±1.7% (range 15% to 29%) to 27.0±1.3% (22% to 36%) (P<0.01 versus baseline/controls) (Figure 1). LVIDs fell from 59.0±2.0 mm (50 to 72 mm) to 55.0±2.1 mm (40 to 68 mm), and LVIDd decreased from 70.1±1.9 mm (60 to 78 mm) to 67.5±1.7 mm (56 to 78 mm) (P<0.05 versus baseline/P=0.2 versus controls). In the IA/IgG group, the mean peripheral arterial blood pressure did not change significantly during follow-up.

After 3 months, examination for NYHA heart failure classification revealed improvement in the IA/IgG group (P<0.05 versus baseline/controls). In contrast, control patients obtained no relief from symptoms.

Histological Findings
Among control patients, the number of lymphocytes (CD3, CD4, and CD8) and of LCA-positive cells in the myocardium remained stable during follow-up (Figure 2A and 2B). Furthermore, no changes in expression of HLA class II antigen were observed.

View larger version (16K): [in this window] [in a new window]   Figure 2. Changes in cellular infiltration in IA/IgG group (solid bars; n=12) and in control group (open bars; n=13). A, CD3-, CD4-, and CD8-positive lymphocytes. B, LCA-positive cells. *P<0.05, **P<0.01 significantly different from baseline; +P<0.05, ++P<0.01 significantly different from controls.

In the IA/IgG group, the number of CD3-positive cells decreased (Figure 2A) from 5.7±0.8 to 2.9±0.5 cells/mm² (P<0.01 versus baseline/controls) within 3 months. This decline was paralleled by a decrease in CD4-positive lymphocytes from 2.3±0.4 to 0.8±0.1 cells/mm² (P<0.01 versus baseline/controls) and in CD8-positive lymphocytes from 2.8±0.5 to 1.8±0.3 cells/mm² (P<0.05 versus baseline/controls) (Figure 2A). These results were also multiply significant according to Bonferroni-Holm. In addition to the reduction of lymphocytes, the number of LCA-positive cells also decreased, from 20.0±3.2 to 9.9±2.8 cells/mm² (P<0.01 versus baseline/P<0.05 versus controls) (Figure 2B). The reduction of inflammatory cells was paralleled by a decline of HLA class II antigen expression from 2.1±0.7% to 1.1±0.4% (P<0.05 versus baseline/controls) (Figure 3).

View larger version (141K): [in this window] [in a new window]   Figure 3. Changes in HLA class II antigen expression of same patient before and after 3-month therapy with IA and subsequent IgG substitution (magnification x400).

In the IA/IgG group and in controls, the degree of fibrosis remained unchanged during follow-up.

	Discussion

Top Abstract Introduction Methods Results Discussion References

 
An association between myocarditis and DCM has been hypothesized for a subset of DCM patients.¹⁹ Abnormalities of the cellular and humoral immune systems are present in these patients.^{4 5} Immunological findings support the hypothesis that the immune process is still active in DCM patients.

IA/IgG treatment induced a reduction of cardiotropic antibodies, as shown by follow-up of the ß-receptor autoantibody level. ß-Receptor autoantibodies modulate the inotropic responsiveness of ß-agonists. These antibodies are capable of attenuating the positive stimulatory effect induced by agonists.¹⁰ In the absence of agonists, however, antibodies induce a positive chronotropic effect in neonatal cardiomyocytes.¹¹ In the present study, analysis of ß-receptor autoantibody was used as a marker for autoimmunological reaction, which occurs in 70% to 90% of DCM patients,^{17 18} and in turn, as a means of evaluating the efficacy of IA. Because the IA columns used in the present study were oriented to IgG in general, no conclusion is possible on whether the observed beneficial effects were due to extraction of a specific antibody (eg, ß-receptor autoantibody).

A number of different cardiac autoantibodies have been identified in patients with myocarditis and DCM.^{8 9 10 11 12 17 18} It is unclear, however, whether these antibodies are directly pathogenic²⁰ or whether they merely represent humoral markers of autoimmunity. In vitro data indicate a negative effect on cardiac performance for certain antibodies.^{8 12} A DCM model was created by immunizing rabbits with peptides of either ß₁-adrenoceptors or M₂ muscarinic receptors. High titers of anti-peptide antibodies were found in the sera. Both groups of immunized rabbits demonstrated heart alterations similar to those found in human DCM.²¹ If cardiac autoantibodies in fact play a role as causal agents in initiating or triggering the disease process, their elimination or blockade would be expected not only to improve myocardial function but also to alleviate the myocardial inflammation observed in DCM.

After plasma IgG depletion induced by IA, IgG was substituted for safety reasons, because the risk of acute infection increases when the IgG level falls below 5 g/dL.²² In addition to IA, IgG treatment also influences the immune system through various mechanisms.¹⁶ Autoantibodies are neutralized by anti-idiotypic properties of intravenous IgG. Furthermore, binding of anti-idiotypic immunoglobulins to B-cell Fc receptors decreases the production of autoantibodies in B cells and thereby prevents a possible rebound phenomenon after IA. Finally, IgG modulates cellular immunity and cytokine metabolism.¹⁶ IgG treatment and IA have been used successfully for treatment of various autoimmune diseases.^{23 24} In addition, IgG substitution after IgG depletion induced by different methods (eg, plasmapheresis) represents a therapeutic option for various autoimmune diseases.²⁵

Treatment with IA/IgG has induced improvement in cardiac function, as revealed in the follow-up in LVEF, and may therefore represent an additional beneficial therapeutic approach in patients with DCM.¹⁴ The present study also demonstrates that IA/IgG therapy induces humoral and cellular alterations of the inflammatory process in the myocardium of DCM patients. Large-scale studies are necessary to clarify the immunohistochemical markers that may predict the efficacy of IA/IgG treatment.

IA/IgG therapy may have influenced cytokine metabolism. Cytokines are recognized as essential markers of immune responses in heart failure.²⁶ Tumor necrosis factor- (TNF-) is able to depress myocardial contractility.²⁷ As previously shown during IA and subsequent IgG therapy, there were no significant alterations in blood serum levels of different proinflammatory cytokines.¹⁴ This result concurs with a previous report on the relevance of TNF- and TNF- I and II receptors in decompensated heart failure and on the effects of clinical interventions on short-term elaboration of this cytokine.²⁸ Despite clinical improvement, the cited report noted no alteration of high peripheral blood levels of TNF-. IA/IgG therapy, however, may have influenced the concentration of cytokines in myocardial tissue. We were not able, however, to perform measurements of tissue concentration of cytokines because of the limited amount of myocardial tissue obtained by biopsies.

The present study successfully excluded the possibility that a decrease in inflammatory cells reflects the natural course of disease, because patients of the control group with similar clinical characteristics demonstrated no change in inflammation. It likewise proved possible to exclude an influence of medical treatment as a cause of these immunohistological alterations, because the patients in the medical-treatment group were stable during the study and because both groups were comparable in this regard. The study disclosed that various histological changes in long-lasting DCM are reversible alterations, eg, infiltration by lymphocytes or increased expression of HLA class II antigen. The reduction in autoantibody level may contribute to the histological alterations observed.

In the present study, a decrease in T lymphocytes was observed in myocardial tissue, a consequence of reduction in CD4 and CD8 cells. Referenced to findings before IA/IgG therapy, the number of leukocytes also decreased. In myocardial tissue of DCM patients, an increased number of leukocytes is associated with altered activation of heart-tissue T cells. This finding suggests a direct role of infiltrating leukocytes in the pathogenesis of DCM.²⁹ Experimental data likewise suggest that inflammation is primarily involved in the disease process of autoimmune myocarditis and DCM: in autoimmune myocarditis induced by myosin, myocardial damage is mediated by T lymphocytes and is strictly dependent on class II antigens of the major histocompatibility complex.⁶ In addition, the impairment of left ventricular function in patients suffering from myocarditis can be transferred to mice by transfer of blood leukocytes.³⁰

In addition to the reduction of inflammatory cells, IA/IgG treatment induced a decline in expression of HLA class II antigens. Expression of class II antigens of the major histocompatibility complex plays an important role in regulation of immune responses, because HLA class II antigens can present peptides to T cells. Furthermore, susceptibility to development of DCM is associated with specific HLA alleles.³¹ Kühl and Schultheiss³² also demonstrated that treatment with 6-methylprednisolone induces reduction of lymphocytic infiltration and HLA class II antigen expression in the myocardium of DCM patients with increased CD3 cell count.

Reduction of fibrosis was observed in patients with end-stage heart failure who were treated with an assist device.³³ The degree of fibrosis remained stable during the present study. In addition, changes have been described in collagen type I/III ratio in biopsies from patients suffering from DCM.³⁴ Our study did not investigate various collagen contents, because biopsies are frequently too small to allow investigation more extended than that involving the parameters analyzed.

Study Limitations
The present study discloses immunohistological changes during IA/IgG therapy in patients suffering from a long-lasting DCM. The number of patients included was too small to assess the important question of whether IA/IgG therapy influences viral elimination. Alterations of a possible virus infection during follow-up were not analyzed because enteroviruses are typically detected in only 26% of DCM cases.³⁵ Furthermore, large-scale studies are necessary to evaluate the relative contributions of IA and IgG treatment to the observed effects.

Conclusions
In DCM patients, myocardial inflammation involving both the cellular and the humoral immune systems can be influenced by IA and subsequent IgG substitution. This therapeutic approach significantly ameliorates the inflammatory process in myocardial tissue and stabilizes myocardial function.

Received December 13, 2000; revision received March 19, 2001; accepted March 21, 2001.

	References

Top Abstract Introduction Methods Results Discussion References

 
1. Richardson P, McKenna W, Bristow M, et al. Report of the 1995 World Health Organization/International Society and Federation of Cardiology Task Force on the Definition and Classification of Cardiomyopathies. Circulation. 1996;93:841–842.[Free Full Text]

2. Kühl U, Seeberg B, Schultheiss HP, et al. Immunohistological characterization of infiltrating lymphocytes in biopsies of patients with clinically suspected dilated cardiomyopathy. Eur Heart J. 1994;15:62–67.

3. Kühl U, Noutsias M, Schultheiss HP. Immunohistochemistry in dilated cardiomyopathy. Eur Heart J. 1995;16:100–106.

4. Limas CJ, Goldenberg IF, Limas C. Soluble interleukin-2 receptor levels in patients with dilated cardiomyopathy: correlation with disease severity and cardiac autoantibodies. Circulation. 1995;91:631–634.[Abstract/Free Full Text]

5. Schwimmbeck PL, Badorff C, Schultheiss HP, et al. Transfer of human myocarditis into severe combined immunodeficiency mice. Circ Res. 1994;75:156–164.[Abstract/Free Full Text]

6. Smith SC, Allen PM. Myosin-induced acute myocarditis is a T-cell mediated disease. J Immunol. 1991;147:2141–2147.[Abstract]

7. Kloppacker G, Mundigler G, Papousek A, et al. Elevated circulating levels of beta-2 microglobulin in patients with idiopathic dilated cardiomyopathy. Am J Cardiol. 1993;71:119–122.[Medline] [Order article via Infotrieve]

8. Schulze K, Becker BF, Schauer R, et al. Antibodies to ADP-ATP carrier—an autoantigen in myocarditis and dilated cardiomyopathy—impair cardiac function. Circulation. 1990;81:959–969.[Abstract/Free Full Text]

9. Caforio AL, Grazzini M, Mann JM, et al. Identification of - and ß-cardiac myosin heavy chain isoforms as major autoantigens in dilated cardiomyopathy. Circulation. 1992;85:1734–1742.[Abstract/Free Full Text]

10. Limas CJ, Goldenberg IF, Limas C. Autoantibodies against ß-adrenoceptors in human idiopathic dilated cardiomyopathy. Circ Res. 1989;64:97–103.[Abstract/Free Full Text]

11. Magnusson Y, Wallukat G, Waagstein F, et al. Autoimmunity in idiopathic dilated cardiomyopathy: characterization of antibodies against the ß₁-adrenoceptor with positive chronotropic effect. Circulation. 1994;89:2760–2767.[Abstract/Free Full Text]

12. Fu LX, Magnusson Y, Bergh CH, et al. Localization of a functional autoimmune epitope on the muscarinic acetylcholine receptor-2 in patients with idiopathic dilated cardiomyopathy. J Clin Invest. 1993;91:1964–1968.

13. Dörffel WV, Felix SB, Wallukat G, et al. Short-term hemodynamic effects of immunoadsorption in dilated cardiomyopathy. Circulation. 1997;95:1994–1997.[Abstract/Free Full Text]

14. Felix S, Staudt A, Dörffel WV, et al. Hemodynamic effects of immunoadsorption and subsequent immunoglobulin substitution in dilated cardiomyopathy: three-month results from a randomized study. J Am Coll Cardiol. 2000;35:1590–1598.[Abstract/Free Full Text]

15. Müller J, Wallukat G, Dandel M, et al. Immunoglobulin adsorption in patients with idiopathic dilated cardiomyopathy. Circulation. 2000;101:385–391.[Abstract/Free Full Text]

16. Dwyer J. Manipulating the immune system with immune globulin. N Engl J Med. 1992;326:107–116.[Medline] [Order article via Infotrieve]

17. Wallukat G, Wollenberger A. Effects of serum gamma globulin fraction in patients with allergic asthma and dilated cardiomyopathy on chronotropic ß-adrenoceptor function in cultured neonatal rat heart myocytes. Biomed Biochim Acta. 1987;46:634–639.

18. Wallukat G, Wollenberger A, Morwinski R, et al. Anti-ß₁-adrenoreceptor autoantibodies with chronotropic activity from the serum of patients with dilated cardiomyopathy: mapping of epitopes in the first and second extracellular loops. J Mol Cell Cardiol. 1995;27:397–406.[Medline] [Order article via Infotrieve]

19. Jin O, Sole MJ, Butany JW, et al. Detection of enterovirus RNA in myocardial biopsies from patients with myocarditis and cardiomyopathy using gene amplification by polymerase chain reaction. Circulation. 1990;82:8–16.[Abstract/Free Full Text]

20. Liao L, Sindhwani R, Rojkind M, et al. Antibody-mediated autoimmune myocarditis depends on genetically determined target organ sensitivity. J Exp Med. 1995;181:1123–1131.[Abstract/Free Full Text]

21. Matsui S, Fu ML, Katsuda S, et al. Peptides derived from cardiovascular G-protein-coupled receptors induce morphological cardiomyopathic changes in immunized rabbits. J Mol Cell Cardiol. 1997;29:641–655.[Medline] [Order article via Infotrieve]

22. Roifman C, Levison H, Gelfand E. High-dose versus low-dose intravenous immunoglobulin in hypogammaglobulinaemia and chronic lung disease. Lancet. 1987;1:1075–1077.[Medline] [Order article via Infotrieve]

23. Grob D, Simpson D, Mitsumoto H, et al. Treatment of myasthenia gravis by immunoadsorption of plasma. Neurology. 1995;45:338–344.[Abstract/Free Full Text]

24. McNamara DM, Rosenblum WD, Janosko KM, et al. Intravenous immune globulin in the therapy of myocarditis and acute cardiomyopathy. Circulation. 1997;95:2476–2478.[Abstract/Free Full Text]

25. Pisani BA, Mullen GM, Malinowska K, et al. Plasmapheresis with intravenous immunoglobulin G is effective in patients with elevated panel reactive antibody prior to cardiac transplantation. J Heart Lung Transplant. 1999;18:701–706.[Medline] [Order article via Infotrieve]

26. Torre-Amione G, Kapadia S, Benedict C, et al. Proinflammatory cytokine levels in patients with depressed left ventricular ejection fraction: a report from the Studies of Left Ventricular Dysfunction (SOLVD). J Am Coll Cardiol. 1996;27:1201–1206.[Abstract]

27. Yokoyama T, Vaca L, Rossen RD, et al. Cellular basis for the negative inotropic effects of tumor necrosis factor- in the adult mammalian heart. J Clin Invest. 1993;92:2303–2312.

28. Milani RV, Mehra MR, Endres S, et al. The clinical relevance of circulating tumor necrosis factor-alpha in acute decompensated chronic heart failure without cachexia. Chest. 1996;110:992–995.[Abstract/Free Full Text]

29. Holzinger C, Schollhammer A, Imhof M, et al. Phenotypic patterns of mononuclear cells in dilated cardiomyopathy. Circulation. 1995;92:2876–2885.[Abstract/Free Full Text]

30. Schwimmbeck PL, Badorff C, Rohn G, et al. Impairment of left ventricular function in combined immune deficiency mice after transfer of peripheral blood leukocytes from patients with myocarditis. Eur Heart J. 1995;16:59–63.

31. Harcombe AA, Sharples L, Large SR, et al. HLA antigen frequencies in end-stage idiopathic and ischaemic cardiomyopathy. Int J Cardiol. 1999;68:31–37.[Medline] [Order article via Infotrieve]

32. Kühl U, Schultheiss HP. Treatment of chronic myocarditis with corticosteroids. Eur Heart J. 1995;16:168–172.

33. Müller J, Wallukat G, Weng G, et al. Weaning from mechanical cardiac support in patients with idiopathic dilated cardiomyopathy. Circulation. 1997;96:542–549.[Abstract/Free Full Text]

34. Pauschinger M, Knopf D, Petschauer S, et al. Dilated cardiomyopathy is associated with significant changes in collagen type I/III ratio. Circulation. 1999;99:2750–2756.[Abstract/Free Full Text]

35. Figulla HR, Stille-Siegener M, Mall G, et al. Myocardial enterovirus infection with left ventricular dysfunction: a benign disease compared with idiopathic dilated cardiomyopathy. J Am Coll Cardiol. 1995;25:1170–1175. [Abstract]

This article has been cited by other articles:

				Y. Matsumoto, I.-K. Park, and K. Kohyama Matrix Metalloproteinase (MMP)-9, but Not MMP-2, Is Involved in the Development and Progression of C Protein-Induced Myocarditis and Subsequent Dilated Cardiomyopathy J. Immunol., October 1, 2009; 183(7): 4773 - 4781. [Abstract] [Full Text] [PDF]

				S. Heymans, E. Hirsch, S. D. Anker, P. Aukrust, J.-L. Balligand, J. W. Cohen-Tervaert, H. Drexler, G. Filippatos, S. B. Felix, L. Gullestad, et al. Inflammation as a therapeutic target in heart failure? A scientific statement from the Translational Research Committee of the Heart Failure Association of the European Society of Cardiology Eur J Heart Fail, February 1, 2009; 11(2): 119 - 129. [Abstract] [Full Text] [PDF]

				O. M. Hess, W. McKenna, and H.-P. Schultheiss CHAPTER 18 Myocardial Disease ESC Textbook of Cardiovascular Medicine, January 1, 2009; 2(1): med-9780199566990-chapter - med-9780199566990-chapter. [Abstract] [Full Text] [PDF]

				L. T. Cooper, K. L. Baughman, A. M. Feldman, A. Frustaci, M. Jessup, U. Kuhl, G. N. Levine, J. Narula, R. C. Starling, J. Towbin, et al. The role of endomyocardial biopsy in the management of cardiovascular disease: A Scientific Statement from the American Heart Association, the American College of Cardiology, and the European Society of Cardiology Endorsed by the Heart Failure Society of America and the Heart Failure Association of the European Society of Cardiology Eur. Heart J., December 2, 2007; 28(24): 3076 - 3093. [Full Text] [PDF]

				L. T. Cooper, K. L. Baughman, A. M. Feldman, A. Frustaci, M. Jessup, U. Kuhl, G. N. Levine, J. Narula, R. C. Starling, J. Towbin, et al. The Role of Endomyocardial Biopsy in the Management of Cardiovascular Disease: A Scientific Statement From the American Heart Association, the American College of Cardiology, and the European Society of Cardiology Endorsed by the Heart Failure Society of America and the Heart Failure Association of the European Society of Cardiology J. Am. Coll. Cardiol., November 6, 2007; 50(19): 1914 - 1931. [Full Text] [PDF]

				L. T. Cooper, K. L. Baughman, A. M. Feldman, A. Frustaci, M. Jessup, U. Kuhl, G. N. Levine, J. Narula, R. C. Starling, J. Towbin, et al. The Role of Endomyocardial Biopsy in the Management of Cardiovascular Disease: A Scientific Statement From the American Heart Association, the American College of Cardiology, and the European Society of Cardiology Circulation, November 6, 2007; 116(19): 2216 - 2233. [Full Text] [PDF]

				A. Frustaci, M. A. Russo, and C. Chimenti Myocarditis in hypertrophic cardiomyopathy: reply Eur. Heart J., July 1, 2007; 28(13): 1664 - 1664. [Full Text] [PDF]

				A. Staudt, P. Eichler, C. Trimpert, S. B. Felix, and A. Greinacher Fc{gamma} Receptors IIa on Cardiomyocytes and Their Potential Functional Relevance in Dilated Cardiomyopathy J. Am. Coll. Cardiol., April 24, 2007; 49(16): 1684 - 1692. [Abstract] [Full Text] [PDF]

				Y. Matsumoto, I.-K. Park, and K. Kohyama B-Cell Epitope Spreading Is a Critical Step for the Switch from C-Protein-Induced Myocarditis to Dilated Cardiomyopathy Am. J. Pathol., January 1, 2007; 170(1): 43 - 51. [Abstract] [Full Text] [PDF]

				J. W. Magnani and G. W. Dec Myocarditis: Current Trends in Diagnosis and Treatment Circulation, February 14, 2006; 113(6): 876 - 890. [Full Text] [PDF]

				G H Stummvoll, M Aringer, J S Smolen, S Schmaldienst, E Jimenez-Boj, W H Horl, W B Graninger, and K Derfler IgG immunoadsorption reduces systemic lupus erythematosus activity and proteinuria: a long term observational study Ann Rheum Dis, July 1, 2005; 64(7): 1015 - 1021. [Abstract] [Full Text] [PDF]

				G. Torre-Amione, F. Sestier, B. Radovancevic, and J. Young Effects of a novel immune modulation therapy in patients with advanced chronic heart failure: Results of a randomized, controlled, phase II trial J. Am. Coll. Cardiol., September 15, 2004; 44(6): 1181 - 1186. [Abstract] [Full Text] [PDF]

				Y. Matsumoto, Y. Tsukada, A. Miyakoshi, H. Sakuma, and K. Kohyama C Protein-Induced Myocarditis and Subsequent Dilated Cardiomyopathy: Rescue from Death and Prevention of Dilated Cardiomyopathy by Chemokine Receptor DNA Therapy J. Immunol., September 1, 2004; 173(5): 3535 - 3541. [Abstract] [Full Text] [PDF]

				A. Staudt, Y. Staudt, M. Dorr, M. Bohm, F. Knebel, A. Hummel, L. Wunderle, M. Tiburcy, K. D. Wernecke, G. Baumann, et al. Potential role of humoral immunity in cardiac dysfunction of patients suffering from dilated cardiomyopathy J. Am. Coll. Cardiol., August 18, 2004; 44(4): 829 - 836. [Abstract] [Full Text] [PDF]

				M Bohm, T Dorner, F Knebel, A Bruns, N Jochmann, and G Baumann Longlasting effects of immunoadsorption in severe Sjogren's syndrome Ann Rheum Dis, February 1, 2004; 63(2): 214 - 215. [Full Text] [PDF]

				M. Noutsias, M. Pauschinger, H.-P. Schultheiss, and U. Kuhl Cytotoxic perforin+ and TIA-1+ infiltrates are associated with cell adhesion molecule expression in dilated cardiomyopathy Eur J Heart Fail, August 1, 2003; 5(4): 469 - 479. [Abstract] [Full Text] [PDF]

				M. Noutsias, M. Pauschinger, H.-P. Schultheiss, and U. Kuhl Advances in the immunohistological diagnosis of inflammatory cardiomyopathy Eur. Heart J. Suppl., December 1, 2002; 4(suppl_I): I54 - I62. [Abstract] [PDF]

				S.B. Felix, A. Staudt, and G. Baumann Immunoadsorption as a new therapeutic principle for treatment of dilated cardiomyopathy Eur. Heart J. Suppl., December 1, 2002; 4(suppl_I): I63 - I68. [Abstract] [PDF]

				U. Kuhl, M. Pauschinger, M. Noutsias, J.-F. Kapp, and H.-P. Schultheiss Diagnosis and treatment of patients with virus induced inflammatory cardiomyopathy Eur. Heart J. Suppl., December 1, 2002; 4(suppl_I): I73 - I80. [Abstract] [PDF]

				A. Staudt, M. Bohm, F. Knebel, Y. Grosse, C. Bischoff, A. Hummel, J. B. Dahm, A. Borges, N. Jochmann, K. D. Wernecke, et al. Potential Role of Autoantibodies Belonging to the Immunoglobulin G-3 Subclass in Cardiac Dysfunction Among Patients With Dilated Cardiomyopathy Circulation, November 5, 2002; 106(19): 2448 - 2453. [Abstract] [Full Text] [PDF]

				S. B. Felix, A. Staudt, M. Landsberger, Y. Grosse, V. Stangl, T. Spielhagen, G. Wallukat, K. D. Wernecke, G. Baumann, and K. Stangl Removal of cardiodepressant antibodies in dilated cardiomyopathy by immunoadsorption J. Am. Coll. Cardiol., February 20, 2002; 39(4): 646 - 652. [Abstract] [Full Text] [PDF]

				N. G. Mahon, B. P. Madden, A. L. P. Caforio, P. M. Elliott, A. J. Haven, B. E. Keogh, M. J. Davies, and W. J. McKenna Immunohistologic evidence of myocardial disease in apparently healthy relatives of patients with dilated cardiomyopathy J. Am. Coll. Cardiol., February 6, 2002; 39(3): 455 - 462. [Abstract] [Full Text] [PDF]

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Staudt, A. Articles by Felix, S. B. Search for Related Content PubMed PubMed Citation Articles by Staudt, A. Articles by Felix, S. B. Related Collections Myocardial cardiomyopathy disease Other Treatment